Trial Profile
A supplementary phase 1b study to evaluate safety, tolerance and exposure of KAND567 administered intravenously in healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs KAND-567 (Primary)
- Indications Autoimmune disorders; Breast cancer; Cancer; Cancer pain; Cardiovascular disorders; Myocardial infarction; Pancreatic cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Kancera
- 19 Feb 2021 Status changed from recruiting to completed, according to a Kancera media release.
- 06 Mar 2020 Results fom the final part of this study published in the Kancera Media Release
- 05 Feb 2020 According to an Kancera media release, the company has received approval from the Finnish Medicines Agency Fimea and the Ethics Committee to start the final part of the phase Ib program for KAND567.The company estimates that the results of the study may become available in March 2020.